This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Aratana Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide.View PETX key stats
Aratana Therapeutics Inc - PETX - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Aratana Therapeutics Inc as a
Sell with a ratings score of D+.
Report Snippet: We rate ARATANA THERAPEUTICS (PETX) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.